[ad_1]
A few years ago, as generics weighed on sales of its three leading cancer drugs, Roche gained early approval for its antibody-drug conjugate Polivy in patients with diffuse large B-cell lymphoma (DLBCL) previously treated. Now the company is looking to position the drug as a first-line treatment – and it says it has the baseline data from a large international study to back it up.
Compared to a placebo, Polivy (polatuzumab vedotin) combined with chemotherapy and a version of Roche’s Rituxan helped patients live longer without making the disease worse, the pharma said Monday morning. Patients in the treatment arm received a combination of cyclophosphamide and doxorubicin chemotherapy with the steroid prednisone (R-CHP), while those in the placebo arm received cyclophosphamide, doxorubicin, vincristine and prednisone (R- CHOP).
[ad_2]
Source link